166 related articles for article (PubMed ID: 30252132)
1. Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer.
Bormann F; Stinzing S; Tierling S; Morkel M; Markelova MR; Walter J; Weichert W; Roßner F; Kuhn N; Perner J; Dietz J; Ispasanie S; Dietel M; Schäfer R; Heinemann V; Sers C
Int J Cancer; 2019 Feb; 144(3):569-581. PubMed ID: 30252132
[TBL] [Abstract][Full Text] [Related]
2. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.
Lee MS; McGuffey EJ; Morris JS; Manyam G; Baladandayuthapani V; Wei W; Morris VK; Overman MJ; Maru DM; Jiang ZQ; Hamilton SR; Kopetz S
Br J Cancer; 2016 Jun; 114(12):1352-61. PubMed ID: 27272216
[TBL] [Abstract][Full Text] [Related]
3.
Kuramochi H; Nakajima GO; Hayashi K; Araida T; Yamamoto M
Anticancer Res; 2019 Sep; 39(9):4729-4736. PubMed ID: 31519572
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
5. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.
Jing C; Jin YH; You Z; Qiong Q; Jun Z
Oncotarget; 2016 Aug; 7(34):55890-55899. PubMed ID: 27344184
[TBL] [Abstract][Full Text] [Related]
7. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Stahler A; Heinemann V; Giessen-Jung C; Crispin A; Schalhorn A; Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Quietzsch D; Held S; von Einem JC; Holch J; Neumann J; Kirchner T; Jung A; Modest DP
Int J Cancer; 2016 Feb; 138(3):739-46. PubMed ID: 26284333
[TBL] [Abstract][Full Text] [Related]
8. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
[TBL] [Abstract][Full Text] [Related]
9. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
[TBL] [Abstract][Full Text] [Related]
10. Integrin α6β4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation.
Carpenter BL; Liu J; Qi L; Wang C; O'Connor KL
Sci Rep; 2017 Jul; 7(1):6174. PubMed ID: 28733611
[TBL] [Abstract][Full Text] [Related]
11. Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in
Williams CJM; Seligmann JF; Elliott F; Shires M; Richman SD; Brown S; Zhang L; Singh S; Pugh J; Xu XM; Muranyi A; Guetter C; Lorsakul A; Kurkure U; Zhao Z; Martin J; Wang X; Nguyen K; Liu WW; Yan D; West NP; Barrett JH; Barnes M; Bai I; Seymour MT; Quirke P; Shanmugam K
Clin Cancer Res; 2021 Jun; 27(12):3422-3431. PubMed ID: 33888518
[TBL] [Abstract][Full Text] [Related]
12. Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.
Williams CJM; Elliott F; Sapanara N; Aghaei F; Zhang L; Muranyi A; Yan D; Bai I; Zhao Z; Shires M; Wood HM; Richman SD; Hemmings G; Hale M; Bottomley D; Galvin L; Cartlidge C; Dance S; Bacon CM; Mansfield L; Young-Zvandasara K; Sudan A; Lambert K; Bibby I; Coupland SE; Montazeri A; Kipling N; Hughes K; Cross SS; Dewdney A; Pheasey L; Leng C; Gochera T; Mangham DC; Saunders M; Pritchard M; Stott H; Mukherjee A; Ilyas M; Silverman R; Hyland G; Sculthorpe D; Thornton K; Gould I; O'Callaghan A; Brown N; Turnbull S; Shaw L; Seymour MT; West NP; Seligmann JF; Singh S; Shanmugam K; Quirke P
Clin Cancer Res; 2023 Oct; 29(20):4153-4165. PubMed ID: 37363997
[TBL] [Abstract][Full Text] [Related]
13. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
Mason JD; Marks E; Fan SJ; McCormick K; Wilson C; Harris AL; Hamdy FC; Cunningham C; Goberdhan DCI
J Extracell Vesicles; 2024 Jun; 13(6):e12465. PubMed ID: 38887984
[TBL] [Abstract][Full Text] [Related]
14. Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer.
Randon G; Pietrantonio F
Clin Cancer Res; 2023 Oct; 29(20):4021-4023. PubMed ID: 37594733
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of cross talk between tissue factor/active coagulation factor VII and epidermal growth factor receptor signalings in colon cancer cells in culture].
Chen HK; Dai Y; Wu T; Wang X; Wan YL; Tang JQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):931-936. PubMed ID: 29263461
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer.
Foroughi S; Hutchinson RA; Wong HL; Christie M; Batrouney A; Wong R; Lee M; Tie J; Burgess AW; Gibbs P
Growth Factors; 2020; 38(3-4):127-136. PubMed ID: 33775193
[TBL] [Abstract][Full Text] [Related]
18. Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.
Qu X; Sandmann T; Frierson H; Fu L; Fuentes E; Walter K; Okrah K; Rumpel C; Moskaluk C; Lu S; Wang Y; Bourgon R; Penuel E; Pirzkall A; Amler L; Lackner MR; Tabernero J; Hampton GM; Kabbarah O
Oncogene; 2016 Dec; 35(50):6403-6415. PubMed ID: 27270421
[TBL] [Abstract][Full Text] [Related]
19. Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.
Sebio A; Páez D; Salazar J; Berenguer-Llergo A; Paré-Brunet L; Lasa A; Del Río E; Tobeña M; Martín-Richard M; Baiget M; Barnadas A
Pharmacogenomics J; 2014 Jun; 14(3):256-62. PubMed ID: 23959273
[TBL] [Abstract][Full Text] [Related]
20. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y
Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
